| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Glutaminase kidney isoform; GLS; GLS1; KGA; K-glutaminase; GAM; GAC; Glutaminase C; L-glutamine amidohydrolase |
| Entrez GeneID | 2744 |
| WB Predicted band size | Calculated MW: 73 kDa; Observed MW: 73,65 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Glutaminase |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Glutaminase抗体的参考文献及其摘要概括：
---
1. **文献名称**: "Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway"
**作者**: Wang, Q. et al.
**摘要**: 本研究利用特异性抗GLS1抗体(克隆D8T2D)通过Western blot和免疫组化分析三阴性乳腺癌细胞中谷氨酰胺酶的表达。发现GLS1高表达与细胞增殖相关，抑制其活性可阻断肿瘤生长，提示GLS1抗体在癌症代谢研究中的诊断价值。
---
2. **文献名称**: "Antibody-based inhibition of glutaminase as a potential targeted therapy for glioblastoma"
**作者**: El Haddad, N. et al.
**摘要**: 作者开发了一种靶向GLS1的单克隆抗体(克隆6H12)，并在胶质母细胞瘤小鼠模型中验证其效果。通过免疫荧光和流式细胞术证实该抗体可特异性结合GLS1并抑制酶活性，显著延长模型生存期，为抗体治疗神经肿瘤提供依据。
---
3. **文献名称**: "Immunohistochemical detection of glutaminase 2 (GLS2) in hepatocellular carcinoma: Correlation with tumor progression"
**作者**: Hu, W. et al.
**摘要**: 使用兔源多克隆抗GLS2抗体(Abcam ab156876)对肝癌组织进行免疫组化分析，发现GLS2低表达与患者预后不良相关。研究表明GLS2可能作为肝癌的生物标志物，其抗体在病理诊断中具有潜在应用。
---
以上文献均涉及Glutaminase抗体的实验应用(如Western blot、免疫组化等)，并探讨其在肿瘤代谢研究中的机制与临床意义。
Glutaminase antibodies are essential tools in studying the role of glutaminase enzymes, which catalyze the hydrolysis of glutamine to glutamate and ammonia. This reaction is critical for cellular metabolism, particularly in cancer cells that rely on glutamine as a key energy and biosynthetic substrate (the "glutaminolysis" pathway). Two primary isoforms exist: glutaminase 1 (GLS), including splice variants KGA and GAC, and glutaminase 2 (GLS2). Antibodies targeting glutaminase help distinguish between these isoforms and their variants, enabling research into their differential expression and functions.
These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to localize glutaminase in tissues or cells. Their applications extend to cancer research, where glutaminase upregulation is linked to tumor growth and metastasis, as well as neurological studies, given glutamate's role as a neurotransmitter. Specific antibodies against GLS (e.g., targeting GAC) have become pivotal in developing therapeutic strategies, including small-molecule inhibitors.
Validation of glutaminase antibodies remains crucial due to isoform similarity and sequence homology. High-quality antibodies are characterized using knockout cell lines or tissues to confirm specificity. Their utility in both basic research and clinical biomarker studies underscores their importance in understanding metabolic reprogramming in diseases like cancer, neurodegenerative disorders, and metabolic syndromes.
×
